Nature2d
US drug agency approves potent painkiller — the first non-opioid in decades
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ...
Imaging research on monoclonal antibodies sheds light on protein dynamics for biopharmaceutical development
Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial ...
Business Wire2d
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...
Future Market Insights2d
Global Antibody Discovery Market Valuation Set to Total USD 21.8 Billion by 2034, Spurred by Escalating Demand for Targeted Therapies | FMI
Phage display remains the most widely used antibody discovery method owing to its versatility, robustness, applicability, and ...
BioPharma Dive5d
Fortis Life Sciences Strengthens Executive Team with Key Appointments
“We are pleased to welcome Darcy and Emily to Fortis,” said Dave King, CEO of Fortis Life Sciences. “Their exceptional leadership, strategic insight, and extensive industry expertise will further ...